Kiora Pharmaceuticals, Inc. (KPRX)

The investment case here is structurally broken. The company has endured five consecutive years of negative annual returns, with the entire nine-year window representing a catastrophic collapse in value. This is not a temporary downturn; the market has repeatedly rejected the business model over nearly a decade, evidenced by the single positive year being an outlier rather than a trend. Fundamentally, the picture is dire: negative earnings, negative free cash flow, and negative returns on both assets and equity indicate a business that is currently destroying capital. While the balance sheet shows low debt relative to equity, the massive negative operating cash flow suggests liquidity risks that outweigh the safety of the books. The recent private placement provides temporary life support, but it does not alter the fundamental reality that the core business is failing to generate value. With no dividend to provide income and a trajectory of consistent decline, there is no rational basis for a long-term hold. For the short term, the stock is trading at a discount to its book value, which offers a theoretical margin of safety, but the lack of any earnings catalyst or proven path to profitability makes any near-term upside speculative at best.